Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

RNDP-001

PreclinicalBiologic

KKenai Therapeutics

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Idiopathic Parkinson´s DiseaseActive, not recruiting

Idiopathic Parkinson´s DiseasePreclinical

Active, not recruiting

Timeline

Expected Milestones

Q2 2031

PreclinicalActive, not recruiting

Idiopathic Parkinson´s Disease

NCT07106021

Clinical

Trials by Indication[1]

Idiopathic Parkinson´s Disease1 trial

A Phase 1b/2a Study Assessing the Safety and Efficacy of Intraputamenal Dopaminergic Stem Cell Transplants in Patients With Idiopathic Parkinson's Disease

Active, not recruiting·KKenai Therapeutics·Preclinical·NCT07106021·12 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for RNDP-001. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — RNDP-001 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for RNDP-001. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Kenai Therapeutics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: KKenai Therapeutics

Related News